The MET axis as a therapeutic target.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The MET receptor tyrosine kinase (RTK) and its ligand, hepatocyte growth factor (HGF), play crucial roles in various malignancies.
• Dysregulated MET/HGF pathway activation contributes to cancer progression, including increased cell growth, invasion, angiogenesis, metastasis, and reduced apoptosis.

Purpose of the Study:

• To summarize the structural requirements for MET signaling and biological functions.
• To describe therapeutic targets and current pre-clinical and clinical approaches for inhibiting the MET/HGF pathway.

Main Methods:

• Review of existing literature on MET receptor tyrosine kinase and HGF signaling.
• Analysis of structural requirements for MET activation and downstream signaling.
• Compilation of data on therapeutic strategies targeting the MET/HGF pathway.

Main Results:

• Ligand-activated MET stimulation can be sufficient for a transforming phenotype.
• Gain-of-function mutations in MET (e.g., in tyrosine kinase, juxtamembrane, or semaphorin domains) lead to deregulated kinase activity and contribute to its transforming potential.
• Various therapeutic strategies targeting MET, including ligand-dependent activation and kinase domain inhibition, are under investigation.

Conclusions:

• Targeting the HGF/MET pathway, either alone or in combination with existing therapies, holds significant promise for improving outcomes in MET-dependent malignancies.
• Understanding the structural basis of MET activation is key to developing effective targeted therapies.